| __timestamp | Incyte Corporation | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 3004000 | 9216000000 |
| Thursday, January 1, 2015 | 26972000 | 8296000000 |
| Friday, January 1, 2016 | 58187000 | 10044000000 |
| Sunday, January 1, 2017 | 79479000 | 11560000000 |
| Monday, January 1, 2018 | 94123000 | 10558000000 |
| Tuesday, January 1, 2019 | 114249000 | 9351000000 |
| Wednesday, January 1, 2020 | 131328000 | 8933000000 |
| Friday, January 1, 2021 | 150991000 | 8284000000 |
| Saturday, January 1, 2022 | 206997000 | 7952000000 |
| Sunday, January 1, 2023 | 255000000 | 8200000000 |
| Monday, January 1, 2024 | 312068000 | 8480000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Teva Pharmaceutical Industries Limited and Incyte Corporation from 2014 to 2023. Over this period, Teva consistently reported higher costs, peaking in 2017 with a 25% increase from 2014. In contrast, Incyte's cost of revenue surged by over 8,400% during the same timeframe, reflecting its rapid growth and expansion efforts. Notably, Teva's costs have shown a downward trend since 2018, decreasing by approximately 31% by 2023, indicating strategic cost management. Meanwhile, Incyte's costs continued to rise, reaching their highest in 2023. This divergence highlights the distinct operational strategies of these companies, offering valuable insights into their financial health and market positioning.
Cost of Revenue: Key Insights for Merck & Co., Inc. and Incyte Corporation
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Teva Pharmaceutical Industries Limited
Cost of Revenue Trends: Teva Pharmaceutical Industries Limited vs Pharming Group N.V.
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Lantheus Holdings, Inc.
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Veracyte, Inc.
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Incyte Corporation vs Intra-Cellular Therapies, Inc.
Cost of Revenue Trends: Incyte Corporation vs Dr. Reddy's Laboratories Limited
Cost of Revenue: Key Insights for Incyte Corporation and Exelixis, Inc.
Cost of Revenue Trends: Incyte Corporation vs Amneal Pharmaceuticals, Inc.
Incyte Corporation vs PTC Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Incyte Corporation and Wave Life Sciences Ltd.